Assessment of disease severity and patient prognosis in anti-GABABR encephalitis with and without comorbid tumors

• DOI: 10.3389/fneur.2023.1201324
• Publication Date: 2023-07-17T23:24:12Z
• Authors: Caiyun Gao; Zhongyun Chen; Huijin Huang; Runxiu Zhu; Yingying Su
• Keywords: Enolase; Carcinoembryonic antigen; Coma (optics)

Purpose This study aimed to analyze the severity of condition and prognosis patients with anti-gamma-aminobutyric-acid type B receptor (anti-GABA R) encephalitis tumors. Methods Patients anti-GABA R admitted one two hospitals from 2020 2022 were enrolled divided into tumor non-tumor groups. The clinical characteristics, severity, treatment options, groups compared analyzed. Results Eighteen included, ten whom had comparison characteristics showed that rates status epilepticus coma significantly higher in group tumors ( P = 0.013 0.025, respectively); incidences pulmonary infection, respiratory failure, hyponatremia, hypoproteinemia also substantially more frequent 0.054, 0.036, 0.015, respectively). laboratory test result serum neuron-specific enolase (NSE) carcinoembryonic antigen (CEA) present only 0.036 0.092, respectively), but there was no significant difference occurrence elevated CEA between Conversely, percentage systemic autoimmune antibodies without than 0.043). tended have poor outcomes 0.152, OR: 7.000). Conclusion Severe brain damage complications occur comorbid Early screening for NSE helps early diagnosis is much worse